cvl-871 cvl-871 cvl-871 is a dopamine receptor agonist which is under development for the treatment of dementia-related apathy. it was originated by pfizer and is under development by cerevel therapeutics. cvl-871 acts as a selective partial agonist of the dopamine d1 and d5 receptors. it is taken via oral administration. as of april 2022, cvl-871 is in phase 2 clinical trials for dementia-related apathy. cvl-871clinical dataroutes ofadministrationoral administrationdrug classdopamine receptor agonist